A follow-up extension study found that participants regained approximately two-thirds of lost weight within one year of stopping treatment, highlighting the importance of sustained therapy (Wilding et al., 2022, PMID: 35441470)
FAQs about generic semaglutide in Canada: Why are generic versions of semaglutide being introduced
Talk with your healthcare provider to see if GLP-1 medications could be right for you
A 2023 analysis of GLP-1 agonist effects found that patients often reported mood improvements coinciding with weight loss and metabolic stabilization
NEW research presented at WCO 2025 has raised concerns about the long-term skeletal safety of GLP-1 receptor agonists (GLP-1 RAs), a class of drugs widely used to manage type 2 diabetes and, more recently, obesity
The presence or absence of B12 affects both your supplementation strategy and your interpretation of injection site reactions or systemic responses